Sign in to continue:

Wednesday, March 18th, 2026

OCBC Bank 2025-2026 Outlook: Strong Synergies, Dividend Momentum & Upgraded BUY Rating | Maybank Research Summary

Broker Name: Maybank Research Pte Ltd
Date of Report: November 7, 2025

Excerpt from Maybank Research Pte Ltd report

Report Summary:

  • Maybank upgrades OCBC Bank to BUY with a raised target price of SGD20.52, citing strong delivery on “One Group” synergies, resilient asset quality, and prospects for higher capital returns.
  • OCBC outperformed earnings expectations for 9M25, driven by robust wealth management and insurance income, with non-interest income and loan growth offsetting net interest margin pressure.
  • The bank’s capital levels are high and provisioning buffers strong, supporting further dividend payouts and potential for continued capital management beyond 2025.
  • Singapore loan growth is the fastest among peers, supported by SME exposure and a construction boom, while asset quality remains solid with industry-leading coverage levels.
  • Maybank expects dividends to remain attractive into 2026, with a projected yield of about 6%, and sees downside support for ROE amid macro volatility thanks to synergies and stable core operations.
  • Risks to the outlook include increased macroeconomic and geopolitical volatility, IT/cyber risks, and currency headwinds from a strong SGD, but overall outlook is positive due to OCBC’s diversification and execution on strategy.

Above is an excerpt from a report by Maybank Research Pte Ltd. Clients of Maybank can be the first to access the full report from the Maybank website: https://www.maybank.com/investment-banking

Bullish Continuation for ComfortDelGro Corp Ltd – Technical Buy Opportunity

Trendspotter: Bullish Continuation and Promising Prospects A...

China CITIC Bank (601998 CH) 2025 Analysis: Dividend Yield, Stable Earnings & Investment Outlook

Broker: OCBC Investment Research Date of Report: 25 June 202...

Elon Musk’s Support for Weight-Loss Drugs Could Propel Eli Lilly Stock: Analysts See 40% Upside

A Presidential Boost for GLP-1s? Eli Lilly's stock, recen...

   Ad